Spanish pharmaceutical company focused on medical dermatology drugs, sold mainly in Europe and the US.
Spanish pharmaceutical company focused on medical dermatology drugs, sold mainly in Europe and the US.
Sells prescription skin drugs through its own sales teams, with Europe the larger base. Much of the range is licensed in from others, such as Ebglyss, an eczema antibody it sells in Europe under licence from Eli Lilly, so partners take a share. It refocused on dermatology after selling its respiratory business to AstraZeneca in 2014.
In one line: A smaller, dermatology-focused specialty pharma.
Moat: narrow (IP / patents, regulatory licence). Patented dermatology drugs give temporary pricing power, eroding once generics enter.
Headquarters: Barcelona, Spain · Founded: 1943 · Employees: 2,108
Size Almirall (ALM.MC) is a Spain Health Care company (Pharmaceuticals: Major) with a market value of $2.46B, the 45th largest of 93 Spain companies the cockpit tracks. Shares closed at €10.32 on 18 Nov 2026.
Performance Over six months the shares fell 12.8%, against -8.4% for the median peer and +5.3% for the Spain market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 24.3% over the last twelve months (peer median +0.1%); the operating margin is 8.4% (peer median 10.6%).
Valuation It trades at 27.1× forward earnings against a peer median of 26.5× (8th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -0 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.3 points below its cost of capital (6.2% WACC).
Credit Almirall has 1 bond outstanding ($277M), rated BB+ by the agencies and trading like A- at a weighted spread of 95 bp.
Next results Next results expected around 22 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €1.15B | €1.11B | €986M | €895M | €863M |
| Revenue growth | — | +12% | +10% | +4% | — |
| Gross profit | €490M | €457M | €394M | €349M | €359M |
| EBITDA | €246M | €219M | €185M | €164M | €174M |
| Net income | €59.1M | €46.2M | €10.1M | -€38.5M | €4.28M |
| Free cash flow | €209M | €134M | €127M | €54.9M | €122M |
| Capital expenditure | €153M | €137M | €161M | €159M | €116M |
| Total debt | €321M | €325M | €390M | €397M | €400M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Almirall ALM.MC | $2.46B | -13% | +24% | 8% | 27.1× | 6.1% |
| Galderma GALD.SW | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% |
| Bausch Health Companies BHC.TO | $3.27B | +66% | +10% | 27% | 2.0× | -14.8% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% |
| Incyte INCY | $24.0B | +21% | +25% | 12% | 15.1× | 14.2% |
| Arcutis Biotherapeutics ARQT | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% |
| Organon & OGN | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 9.7× | -4.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALM.MC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.2% | -5.5% | 8th highest of 21 |
| 6-month return | -12.8% | -8.4% | 8th lowest of 21 |
| Distance from 52-week high | -26.2% | -28.5% | 10th highest of 21 |
| Revenue growth (TTM) | +24.3% | +0.1% | 4th highest of 20 |
| Operating margin | 8.4% | 10.6% | 9th lowest of 19 |
| Forward P/E | 27.1× | 26.5× | 8th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 6.1% | 18.7% | 7th least demanding of 15 |
| Growth delivered (Del g) | +6.5% | +5.5% | 6th highest of 15 |
| Hurdle (Req g minus delivered) | -0.5 pp | +6.3 pp | 6th least demanding of 15 |
| ROIC minus cost of capital | -1.3 pp | -2.1 pp | 8th highest of 15 |
| EV / EBITDA | 9.0× | 13.7× | 2nd cheapest of 4 |
| Net debt / EBITDA | -0.1× | 2.9× | 2nd least indebted of 5 |
| Bond spread | 95 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Almirall ALM.MC | Spain | $2.46B | -13% | +24% | 8% | 27.1× | 6.1% | +6.5% |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.49B | -24% | -14% | 16% | 27.6× | 3.4% | +4.8% |
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 10.6× | 2.3% | +2.9% |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.40B | -33% | +153% | -7% | 85.2× | 37.9% | +22.9% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.39B | +7% | 0% | -73% | 18.2× | n/a | n/a |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.38B | +14% | -9% | -6% | 35.9× | 47.0% | +19.3% |
| IDEAYA Biosciences IDYA | United States | $2.56B | -11% | -83% | -1,267% | n/a | n/a | n/a |
| NewAmsterdam Pharma NAMS | United States | $2.37B | -45% | -26% | -900% | n/a | n/a | n/a |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.36B | -66% | +23% | 7% | n/a | n/a | n/a |
| Perrigo PRGO | United States | $2.35B | +52% | -4% | 5% | 6.7× | 14.1% | +0.8% |
| Kangmei Pharmaceutical 600518.SS | China | $2.61B | -21% | -6% | -7% | n/a | n/a | n/a |
| Regencell Bioscience RGC | United States | $2.33B | -83% | n/a | n/a | n/a | n/a | n/a |
| Acrobiosystems 301080.SZ | China | $2.31B | +65% | +29% | 17% | 55.2× | 41.3% | +27.7% |
| BioArctic BIOA-B.ST | Sweden | $2.66B | -9% | -46% | 22% | 52.9× | 25.5% | +100.1% |
| Hybio Pharmaceutical 300199.SZ | China | $2.68B | -8% | +70% | 31% | 44.7× | 37.4% | +6.1% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.25B | -7% | +4% | 10% | n/a | -2.5% | -5.8% |
| Betta Pharmaceuticals 300558.SZ | China | $2.70B | -15% | +16% | 11% | 38.0× | 23.2% | +14.0% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 25.0× | 26.7% | +6.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 25.4× | 0.9% | +0.3% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% | -1.5% |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.85B | 0% | -12% | 18% | 15.5× | -13.1% | +2.4% |
Almirall has 1 bond outstanding with $277M face value. The agencies rate it BB+; its bonds trade like A-. Weighted yield 4.36%, a spread of 95 bp over government bonds.